Last 28 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -12.68 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 3.62 | 3.05 | 2.71 | 2.34 | 1.70 | 1.44 | 1.60 | 3.04 | 4.14 | 4.46 | 3.85 | 5.29 | 3.70 | 3.42 | 3.42 | 3.80 | 4.14 | 3.61 | 3.87 | 4.58 | 4.33 |
| — | +111.5% | +69.0% | -23.1% | -59.0% | -67.7% | -58.4% | -42.5% | +11.9% | +30.5% | +12.4% | +39.2% | -10.8% | -5.4% | -11.5% | -17.1% | -4.5% | -1.3% | +25.0% | +17.1% | -37.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -25.6% | -9.9% | -11.3% | -8.8% | -7.1% | -5.3% | -4.3% | -4.1% | -3.8% | -6.5% | -5.9% | -13.7% | -6.5% | -5.7% | -6.4% | -11.9% | -16.0% | -13.4% | -12.1% | -9.7% | -8.5% |
| — | -86.0% | -160.9% | -116.7% | -87.0% | +18.1% | +26.6% | +70.2% | +41.6% | -12.8% | +7.5% | -15.1% | +59.1% | +57.0% | +47.4% | -22.8% | -86.8% | -81.8% | -92.1% | -65.7% | -51.9% | |
| ROA | -23.4% | -8.8% | -10.0% | -7.9% | -6.6% | -5.0% | -4.1% | -3.9% | -3.7% | -6.2% | -5.4% | -12.5% | -6.2% | -5.4% | -6.0% | -11.0% | -14.1% | -11.9% | -10.7% | -8.4% | -7.5% |
| — | -75.9% | -145.5% | -104.5% | -79.9% | +19.1% | +24.8% | +68.9% | +40.9% | -13.2% | +9.5% | -13.1% | +56.1% | +54.3% | +44.0% | -30.7% | -88.1% | -86.4% | -95.9% | -61.7% | -45.8% | |
| ROIC | -24.2% | -8.2% | -9.3% | -7.6% | -6.6% | -5.9% | -4.6% | -4.5% | -5.4% | -7.9% | -7.6% | -16.9% | -9.5% | -8.7% | -14.9% | -54.7% | -35.1% | -21.8% | -14.3% | -10.5% | -11.2% |
| — | -39.9% | -102.8% | -67.5% | -21.4% | +26.1% | +39.5% | +73.3% | +43.0% | +9.1% | +49.2% | +69.0% | +73.0% | +60.0% | -4.2% | -421.2% | -214.5% | -81.2% | +63.5% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.04 | 0.04 | 0.09 | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.06 | 0.06 | 0.06 | 0.06 | 0.00 |
| — | +49.8% | +42.4% | +296.1% | +256.8% | +117.0% | +97.2% | -8.7% | -16.9% | +21.4% | -21.3% | +25.2% | -82.1% | -81.7% | -71.8% | -68.2% | +1344.6% | +1861.9% | +1706.6% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.91 | 5.72 | 7.49 | 7.91 | 8.83 | 11.11 | 17.70 | 12.75 | 17.88 | 17.88 | 17.42 | 7.54 | 15.14 | 21.76 | 15.94 | 23.26 | 9.41 | 11.94 | 12.56 | 8.93 | 6.38 |
| — | -48.5% | -57.7% | -38.0% | -50.6% | -37.9% | +1.6% | +69.1% | +18.1% | -17.8% | +9.3% | -67.6% | +61.0% | +82.3% | +26.9% | +160.5% | +47.4% | +61.2% | +112.8% | +7.5% | -36.9% | |
| Quick Ratio | 7.91 | 5.72 | 7.49 | 7.91 | 8.83 | 11.11 | 17.70 | 12.75 | 17.88 | 17.88 | 17.42 | 7.54 | 15.14 | 21.76 | 15.94 | 23.26 | 9.41 | 11.94 | 12.56 | 8.93 | 6.38 |
| — | -48.5% | -57.7% | -38.0% | -50.6% | -37.9% | +1.6% | +69.1% | +18.1% | -17.8% | +9.3% | -67.6% | +61.0% | +82.3% | +26.9% | +160.5% | +47.4% | +61.2% | +112.8% | +7.5% | -36.9% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -24265.00 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PCVX stock.
Vaxcyte, Inc.'s current P/E is -12.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Vaxcyte, Inc.'s business trajectory between earnings reports.